Cytomegalovirus peptide-HLA complex (CMV-pHLA)

The Cytomegalovirus (CMV) peptide-HLA complex is the primary molecular target for cellular immunity against Human Cytomegalovirus (HCMV) (Arvin et al., 2007). During infection, viral proteins such as pp65 and IE1 are processed into short peptides and presented on the cell surface by HLA Class I and II molecules (Wills et al., 1996). This presentation allows the immune system to identify and eliminate infected cells through T-cell receptor (TCR) recognition. In immunocompromised individuals, such as transplant recipients, the lack of effective T-cell recognition of these complexes leads to uncontrolled viral replication and severe disease (Tzannou et al., 2017). Therapeutic strategies like virus-specific T-cell (VST) therapy, including drugs like Posoleucel, specifically target these complexes to restore antiviral immunity (AlloVir, 2023). Additionally, engineered TCR-T cells and TCR-like antibodies are being developed to bind these complexes with high specificity. The target is highly specific to infected cells, minimizing damage to healthy, non-infected tissues. However, the diversity of HLA alleles across the human population requires HLA-matching for many of these therapies to be effective. Monitoring CMV viral load and HLA status is critical for patient selection and assessing treatment efficacy. Overall, the CMV peptide-HLA complex is a cornerstone of modern immunotherapy for managing CMV in high-risk clinical settings.

Other names

CMV peptide-MHC complexCMV-infected cell surface antigensHCMV peptide-HLApp65-HLA complexIE1-HLA complexCMV-specific peptide-HLA

Binding of therapeutic T-cell receptors (TCRs) to the peptide-HLA complex on the surface of infected cells, leading to cytotoxic T-lymphocyte (CTL) activation and subsequent lysis of the CMV-infected cell.